John La Mattina
About John La Mattina
John La Mattina is a seasoned director with extensive experience in the pharmaceutical industry, currently serving as a Director at Ligand Pharmaceuticals. He has held various leadership roles at Pfizer and other biopharmaceutical companies, contributing significantly to drug development and research operations.
Current Role at Ligand Pharmaceuticals
John La Mattina serves as Director at Ligand Pharmaceuticals, a position he has held since 2008. In this role, he contributes to the strategic direction and operational management of the company. Ligand Pharmaceuticals focuses on developing technologies that enhance the drug discovery and development process.
Previous Experience at Immunome, Inc.
Prior to his current role, La Mattina worked as Director at Immunome, Inc. from 2017 to 2023. His tenure at Immunome involved overseeing various projects and initiatives aimed at advancing the company's therapeutic pipeline. Immunome, based in Exton, Pennsylvania, specializes in developing immune-based therapies.
Education and Expertise
John La Mattina graduated cum laude with a Bachelor of Science in Chemistry from Boston College. He furthered his education by obtaining a Ph.D. in Organic Chemistry from the University of New Hampshire. Additionally, he completed a postdoctoral fellowship in Organic Chemistry at Princeton University, which provided him with advanced research training.
Career at Pfizer
La Mattina spent 30 years at Pfizer, where he held various leadership roles, including President of R&D and Senior Vice President of Worldwide Development. His career at Pfizer began as a medicinal chemist in 1977, and he progressed through positions of increasing responsibility, culminating in his role as President of Pfizer Global R&D starting in 2004.
Board Memberships and Advisory Roles
In addition to his corporate roles, John La Mattina serves on the boards of directors of Immunome, Inc. and several privately-held biopharmaceutical companies. He is also a senior advisor and board member at PureTech Health and serves on the scientific advisory board of Frequency Therapeutics, contributing his expertise to the biopharmaceutical industry.